Literature DB >> 17579074

Prophylactic and therapeutic use of antibodies for protection against respiratory infection with Francisella tularensis.

Girish S Kirimanjeswara1, Jacqueline M Golden, Chandra Shekhar Bakshi, Dennis W Metzger.   

Abstract

The role of Abs in protection against respiratory infection with the intracellular bacterium Francisella tularensis is not clear. To investigate the ability of Abs to clear bacteria from the lungs and prevent systemic spread, immune serum was passively administered i.p. to naive mice before intranasal F. tularensis live vaccine strain infection. It was found that immune serum treatment provided 100% protection against lethal challenge while normal serum or Ig-depleted immune serum provided no protection. Protective efficacy was correlated with increased clearance of bacteria from the lung and required expression of FcgammaR on phagocytes, including macrophages and neutrophils. However, complement was not required for protection. In vitro experiments demonstrated that macrophages were more readily infected by Ab-opsonized bacteria but became highly efficient in killing upon activation by IFN-gamma. Consistent with this finding, in vivo Ab-mediated protection was found to be dependent upon IFN-gamma. SCID mice were not protected by passive Ab transfer, suggesting that T cells but not NK cells serve as the primary source for IFN-gamma. These data suggest that a critical interaction of humoral and cellular immune responses is necessary to provide sterilizing immunity against F. tularensis. Of considerable interest was the finding that serum Abs were capable of conferring protection against lethal respiratory tularemia when given 24-48 h postexposure. Thus, this study provides the first evidence for the therapeutic use of Abs in Francisella-infected individuals.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17579074     DOI: 10.4049/jimmunol.179.1.532

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  75 in total

1.  Defective anti-polysaccharide IgG vaccine responses in IgA deficient mice.

Authors:  Yoichi Furuya; Girish S Kirimanjeswara; Sean Roberts; Rachael Racine; Jennifer Wilson-Welder; Alan M Sanfilippo; Sharon L Salmon; Dennis W Metzger
Journal:  Vaccine       Date:  2017-07-31       Impact factor: 3.641

2.  Detrimental Influence of Alveolar Macrophages on Protective Humoral Immunity during Francisella tularensis SchuS4 Pulmonary Infection.

Authors:  Donald J Steiner; Yoichi Furuya; Dennis W Metzger
Journal:  Infect Immun       Date:  2018-03-22       Impact factor: 3.441

3.  Detoxified endotoxin vaccine (J5dLPS/OMP) protects mice against lethal respiratory challenge with Francisella tularensis SchuS4.

Authors:  Stephen H Gregory; Wilbur H Chen; Stephanie Mott; John E Palardy; Nicholas A Parejo; Sara Heninger; Christine A Anderson; Andrew W Artenstein; Steven M Opal; Alan S Cross
Journal:  Vaccine       Date:  2010-02-17       Impact factor: 3.641

4.  Antibodies contribute to effective vaccination against respiratory infection by type A Francisella tularensis strains.

Authors:  Gopi Mara-Koosham; Julie A Hutt; C Rick Lyons; Terry H Wu
Journal:  Infect Immun       Date:  2011-01-31       Impact factor: 3.441

5.  The presence of infectious extracellular Francisella tularensis subsp. novicida in murine plasma after pulmonary challenge.

Authors:  J-J Yu; E K Raulie; A K Murthy; M N Guentzel; K E Klose; B P Arulanandam
Journal:  Eur J Clin Microbiol Infect Dis       Date:  2007-12-18       Impact factor: 3.267

6.  Generation and characterization of hybridoma antibodies for immunotherapy of tularemia.

Authors:  Zhaohua Lu; Marly I Roche; Julia H Hui; Berkay Unal; Philip L Felgner; Sunita Gulati; Guillermo Madico; Jacqueline Sharon
Journal:  Immunol Lett       Date:  2007-08-08       Impact factor: 3.685

7.  Francisella tularensis infection-derived monoclonal antibodies provide detection, protection, and therapy.

Authors:  Anne G Savitt; Patricio Mena-Taboada; Gloria Monsalve; Jorge L Benach
Journal:  Clin Vaccine Immunol       Date:  2009-01-28

8.  Francisella tularensis subsp. tularensis Schu S4 disulfide bond formation protein B, but not an RND-type efflux pump, is required for virulence.

Authors:  Aiping Qin; David W Scott; Barbara J Mann
Journal:  Infect Immun       Date:  2008-05-05       Impact factor: 3.441

9.  Inhibitors of Ribosome Rescue Arrest Growth of Francisella tularensis at All Stages of Intracellular Replication.

Authors:  Tyler D P Goralski; Kalyan K Dewan; John N Alumasa; Victoria Avanzato; David E Place; Rachel L Markley; Bhuvana Katkere; Seham M Rabadi; Chandra Shekhar Bakshi; Kenneth C Keiler; Girish S Kirimanjeswara
Journal:  Antimicrob Agents Chemother       Date:  2016-05-23       Impact factor: 5.191

10.  Identification of an essential Francisella tularensis subsp. tularensis virulence factor.

Authors:  Aiping Qin; David W Scott; Jennifer A Thompson; Barbara J Mann
Journal:  Infect Immun       Date:  2008-11-03       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.